Heidelberg University Hospital (NCT Heidelberg): Cancer Care

The National Center for Tumor Diseases Heidelberg was established in 2004 to bring cancer research and patient care into closer collaboration. Its partnership with Heidelberg University Hospital and DKFZ supports the evaluation of research findings in clinical practice, including molecularly informed approaches to treatment.

NCT Heidelberg is part of a wider academic cancer-care structure, not a stand-alone facility where all investigations and procedures occur. Surgery, radiotherapy, haematology, inpatient care and other services are provided through the appropriate hospital departments. Patients may therefore have appointments at more than one location or with several specialist teams.

Its scale is best understood through this broad hospital and research network rather than a single bed count. Multidisciplinary tumour boards bring together specialists to review diagnosis, disease extent and treatment options. Recommendations may include standard treatment, further diagnostic work, supportive care or assessment for a clinical study.

The centre is particularly associated with precision oncology, the MASTER molecular diagnostics and tumour-board programme, and access to HIT. These resources can support complex case assessment, but their relevance depends on the individual cancer and treatment history; they do not imply that an experimental or highly specialised treatment will be recommended.

Relevant specialist areas include liver, pancreatic, lung and breast cancers. Assessment may involve medical oncology, surgery, radiology, pathology and radiotherapy, with treatment planning influenced by stage, operability, molecular findings and general health. For liver cancer, underlying liver function is also important; for pancreatic cancer, specialist review may help clarify whether surgery or another treatment sequence is appropriate.

Rare cancers and cancers occurring in younger adults are important areas of molecular oncology work. MASTER can provide comprehensive molecular characterisation for selected patients, followed by multidisciplinary interpretation. A finding may suggest an established treatment, an off-label option or a trial, but testing does not always identify an actionable result.

Blood cancer services include specialist haematological assessment and treatment. Depending on the diagnosis, options may involve drug combinations, transplantation or cellular therapies. CAR-T assessment is relevant to particular blood cancers and treatment settings, rather than to blood cancers as a whole.

Cancer treatment across Heidelberg University Hospital includes surgery, systemic drug treatment and radiotherapy, alongside symptom management and supportive care. The recommended combination depends on whether treatment aims to cure the cancer, reduce recurrence risk, control advanced disease or relieve symptoms. Patients should ask which team would coordinate their care.

Precision oncology uses tumour characteristics to inform treatment choices. Molecular testing may identify a target for an approved targeted therapy or support consideration of a study. Immunotherapy is another established option for selected cancers, sometimes guided by biomarkers. Neither approach is automatically preferable to standard chemotherapy, and a molecular match does not guarantee benefit.

HIT provides particle radiotherapy, including proton and carbon-ion treatment. These techniques can offer useful radiation dose distributions for selected situations, particularly where protecting nearby normal tissues is important. Suitability requires specialist radiation oncology review and comparison with other approaches. Proton therapy is not routinely indicated for every cancer listed in this profile.

CAR-T therapy is available through specialist haematology services for eligible patients with certain blood cancers. It requires detailed assessment, preparation and close monitoring because serious adverse effects can occur. Clinical trials may provide additional treatment options, but participation involves a research protocol and uncertain benefit. Rehabilitation, nutritional advice, psycho-oncology and palliative care may also be relevant during treatment.

The oncology research portfolio spans different cancer types and study designs, including investigations of new medicines, treatment combinations, biomarkers and molecularly selected therapies. Around 450 active oncology clinical trials is an indicative figure supplied for this profile; it is not a verified live recruitment count. The total may vary with reporting date, institutional scope and whether studies are recruiting, following participants or otherwise active.

International patients can ask for trial consideration during specialist records review. Eligibility commonly depends on exact pathology, stage, previous treatments, biomarkers, organ function and functional status. Some studies require additional testing or local confirmation of pathology. A potentially relevant study may have no open places, and residence, insurance or follow-up requirements can affect participation.

Ask for the study identifier, recruiting status, treatment schedule and expected visits. Clarify which research-related expenses are covered and which routine care, travel or accommodation costs remain payable. Do not interrupt current treatment solely in anticipation of joining a trial.

Start with a records-based enquiry through the hospital's official channels. Explain the confirmed diagnosis, previous treatment, current condition and whether you want a second opinion, a specific procedure or trial assessment. Ask which service should receive the referral and whether remote review is possible before travel. Complex molecular or pathology questions may need additional material before a useful recommendation can be made.

Once an assessment is offered, obtain a written plan covering its scope, likely investigations, financial arrangements and follow-up responsibilities. Confirm whether treatment could require an extended stay or a companion. Discuss travel fitness with the treating team at home and arrange continuity of care after return, including access to medicines, monitoring and urgent advice. Assessment at Heidelberg does not guarantee acceptance for treatment.

Contact details below come from the hospital's own published international patient information.

Location: Heidelberg, Germany

Email: international.office@med.uni-heidelberg.de

Phone: +49 6221 56 0

Website: https://www.klinikum.uni-heidelberg.de

Languages supported: German, English, Russian, Arabic

Remote second opinion: Available

Always confirm current contact details on the hospital's own website before sending medical records, and never send documents to an address you have not verified.